InVitae (NYSE: NVTA) reported Q4 EPS of ($0.40), $0.05 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $45.36 million versus the consensus estimate of $40.78 million.
“In just five years, we have provided more than half a million people with high quality, comprehensive, affordable genetic information to inform healthcare decisions across all stages of life,” said Sean George, co-founder and chief executive officer of Invitae. “We believe we’re on an unprecedented growth trajectory that translates into better health decisions informed by genetic information. Our seemingly audacious mission to bring genetics into mainstream medicine and benefit people through all stages of life, is coming into clear focus – not only in diagnosing disease, but in helping people as they think about starting a family or informing those who want to be proactive about their health.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.